Journal article
Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy
Transplant infectious disease, Vol.15(1), pp.E33-E39
02/01/2013
DOI: 10.1111/tid.12048
PMID: 23278987
Abstract
Mycobacterium tuberculosis infection is one of many opportunistic infections in renal transplant recipients, arising either from reactivation of latent infection or de novo infection, occasionally donor derived. M. tuberculosis hepatitis has never been reported in patients who have received alemtuzumab as part of their renal transplant management. We describe 2 patients who underwent deceased-donor renal transplantation following alemtuzumab induction therapy and presented with a febrile syndrome, subsequently diagnosed as tuberculous hepatitis, one with disseminated disease. Both responded well to treatment without significant side effects, resulting in excellent graft function. The importance of chemoprophylaxis should be emphasized to minimize the risk of developing active tuberculosis in patients with latent tuberculosis infection undergoing solid organ transplantation.
Details
- Title: Subtitle
- Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy
- Creators
- W. Bosch - Mayo Clinic in FloridaN. Poowanawittayakom - Siriraj HospitalK. Chaikriangkrai - Siriraj HospitalJ. Mendez - Mayo Clinic in FloridaW. C. Hellinger - Mayo Clinic in FloridaT. A. Gonwa - Department of Transplantation, Mayo Clinic , Jacksonville, Florida , USA.M. Krishna - Department of Pathology, Mayo Clinic, Jacksonville, Florida, USA.S. Pungpapong - Department of Transplantation, Mayo Clinic , Jacksonville, Florida , USA.
- Resource Type
- Journal article
- Publication Details
- Transplant infectious disease, Vol.15(1), pp.E33-E39
- Publisher
- Wiley
- DOI
- 10.1111/tid.12048
- PMID
- 23278987
- ISSN
- 1398-2273
- eISSN
- 1399-3062
- Number of pages
- 7
- Language
- English
- Date published
- 02/01/2013
- Academic Unit
- Cardiovascular Medicine; Internal Medicine
- Record Identifier
- 9984359570602771
Metrics
5 Record Views